Generated by All in One SEO Pro v4.9.6.1, this is an llms.txt file, used by LLMs to index the site.

# Juvenescence

Extending Healthy Lifespan

## Sitemaps

- [XML Sitemap](https://juvlabs.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor](https://juvlabs.com/news/press-releases/juvenescence-completes-phase-1-trial-of-pai-1-inhibitor/) - Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following recent appointments of Paul Russell as Chief Development
- [Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy](https://juvlabs.com/news/videos/dr-greg-bailey-interview/)
- [Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City's Life Science Innovation Cluster](https://juvlabs.com/news/press-releases/juvenescence-appoints-eileen-jennings-brown-as-cto-expands-in-uae-presence-with-masdar-city/) - Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City Jennings-Brown will drive AI and technology strategy and lead the development of capabilities enabling discovery of therapeutics targeting fundamental aging mechanisms Offices in Abu Dhabi's premier biotechnology hub to support the build-out of an
- [Richards interview to Jo Shorthouse](https://juvlabs.com/news/in-the-news/richards-interview-to-jo-shorthouse/) - 💬 There’s still capital out there – it’s just coming from new directions. Our CEO, Richard Marshall CBE, shares his insights on the evolving biotech funding landscape and where companies like Juvenescence are finding opportunity amid the VC pullback by forging strategic partnerships in markets that value deep R&D expertise. 👇 Read the insightful piece
- [New Medicines for the Healthspan Revolution | M42](https://juvlabs.com/news/videos/new-medicines-for-the-healthspan-revolution-m42/) - https://www.youtube.com/watch?v=FKrjMToSbjw
- [Demystifying Biotechnology: A Deep Dive into Juvenescence | M42](https://juvlabs.com/news/videos/demystifying-biotechnology-a-deep-dive-into-juvenescence-m42/) - https://www.youtube.com/watch?v=p_GDB_YwAIg
- [Greg Bailey: Biotech can add another 10 healthy years to your life](https://juvlabs.com/news/videos/greg-bailey-biotech-can-add-another-10-healthy-years-to-your-life/) - https://www.youtube.com/watch?v=_PwOWvX1UIE
- [Juvenescence: Think aging up, rather than disease down](https://juvlabs.com/news/videos/juvenescence-think-aging-up-rather-than-disease-down-2/) - https://www.youtube.com/watch?v=bOLVqSX2-VU
- [Presenting at several conferences in the UAE](https://juvlabs.com/news/juv-on-the-road/few-conferences-in-the-uae/) - Juvenescence has carried positive momentum into 2026 following a series of invigorating conferences in hashtag#AbuDhabi, where our team joined discussions on shaping the future of hashtag#longevity and advancing hashtag#healthspan. At the Revive ME Longevity Conference, our CEO, Richard Marshall CBE explored how advances in research could help redefine human healthspan over the next 20 years, alongside the UAE’s emergence as a leading hub for research and innovation.
- [Eric Verdin, our collaborator in the Buck institute presents data on our compound](https://juvlabs.com/news/juv-on-the-road/eric-verdin-our-collaborator-in-the-buck-institute-presents-data-on-our-compound/) - We were pleased to attend the Longevity Summit 2025 at the Buck Institute for Research on Aging, a vibrant gathering of leaders across aging science, biotechnology, and translational research, united by a shared commitment to advancing healthy aging. We were delighted to see Dr. Eric Verdin, President & CEO of the Buck Institute, present compelling
- [Jim Mellon presenting at UBS Year Ahead conference](https://juvlabs.com/news/juv-on-the-road/jim-mellon-presenting-at-ubs-year-ahead-conference/) - At the recent UBS Year Ahead 2026 flagship event, our Co-Founder Jim Mellon joined to discuss how advances in longevity science are reshaping global health. He highlighted how demographic shifts, scientific breakthroughs, and emerging therapeutics are converging to redefine healthy lifespan. We're encouraged to see longevity increasingly recognised as a core pillar of global economic
- [We are proud to Sponsor and host The Longevity forum in London](https://juvlabs.com/news/juv-on-the-road/sponsor-and-host-longevity-forum/) - We are proud to sponsor The Longevity Forum in London last week - bringing together leaders in science, policy & innovation to advance the future of healthy ageing. Highlights included thoughtful discussions on funding preventative health, reimagining work across a longer lifespan, and how consumers can better engage with longevity science. As Juvenescence® continues advancing
- [Our Director of IR, Yehudah Nevies, presenting at Singapore Week of Innovation & Technology](https://juvlabs.com/news/juv-on-the-road/yehudah-director-of-ir-presented-at-singapore-week-of-innovation-and-technology/) - An incredible week in Singapore 🇸🇬 - grateful to HSBC Innovation Banking , Christina Lee & Kerri L. for the opportunity to present Juvenescence® during the buzzing Singapore Week of Innovation and Technology (SWITCH). I also had the pleasure of visiting the new Clinical Trial Center at the NUS Academy for Healthy Longevity. It's inspiring
- [Jim on Panel at Abu Dhabi Investment Forum in London](https://juvlabs.com/news/juv-on-the-road/jim-on-panel-at-abu-dhabi-investment-forum-in-london/) - Engineering the Future of Health in Abu Dhabi 🧬 Our Deputy Chairman & Co-founder Jim Mellon spoke at the Abu Dhabi Investment Forum in London, joining a distinguished panel alongside Dimitris Moulavasilis (M42 Health) and Georges-Pascal Haber (Cleveland Clinic Abu Dhabi). Jim highlighted Abu Dhabi's unique position at the intersection of data, technology & investment
- [Our CSO, Gill Dines at ARDD Conference](https://juvlabs.com/news/juv-on-the-road/gill-at-ardd-conference/) - Exciting to see such strong global interest in healthspan science at the Aging Research & Drug Discovery Meeting (ARDD) 2025 conference in Copenhagen last week. Our CSO, Gill Dines, joined leading voices from biotech, big pharma, research institutes, policymakers, and academics to discuss how we can translate cutting-edge science into new medicines and insights that
- [Rosalba presenting data from our core medicine](https://juvlabs.com/news/juv-on-the-road/rosalba-presenting-data-from-our-core-medicine/) - 🧬 This week our Senior Research Scientist Rosalba Perrone , Ph.D presented exciting new data from our CD38 inhibitor program at the 2025 Gordon Research Conferences on the Biology of Aging, alongside co-authors from our collaborators at the Buck Institute for Research on Aging. They shared new data highlighting how CD38 inhibition may enhance cognitive
- [Chrysea presents additional study results at Gordon Research Conference (GRC)](https://juvlabs.com/news/in-the-news/chrysea-news/) - At BFLS, significant associations reported in a large representative cohort of 8965 Americans between higher spermidine intake levels and lower cardiovascular risk markers were reported to be independent of BMI (Body Mass Index) levels. At GRC, significant associations (P
- [Team at Middle East Investors Summit](https://juvlabs.com/news/juv-on-the-road/team-at-middle-east-investors-summit/) - We were glad to participate in the recent Middle East Investors Summit - a dynamic gathering of global investors, family offices, and innovators in Abu Dhabi. This forum provided a powerful platform to engage on the future of life-sciences in the region and the sessions led by The Emirates Family Office Association & New York
- [Relation Therapeutics announces $1.7B strategic collaboration with Novartis to advance therapeutics for Atopic Diseases](https://juvlabs.com/news/in-the-news/relation-therapeutics-announces-1-7b-strategic-collaboration-with-novartis-to-advance-therapeutics-for-atopic-diseases/) - Fantastic news from Relation, announcing a strategic collaboration with Novartis of up to $1.7 billion to discover and advance novel targets for atopic diseases. A powerful validation of the Relation platform and its growing momentum through mutliple high-value pharma partnerships. This collaboration combines Relation’s AI-driven biology engine with Novartis’s deep immuno-dermatology expertise to develop novel
- [Greg at Founders forum](https://juvlabs.com/news/juv-on-the-road/greg-at-founders-forum/) - Our co-founder, Dr. Greg Bailey, shared key insights on longevity science and the latest exciting developments at Juvenescence® during the Founders Forum Global 20th Anniversary Summit. It was an incredible gathering that addressed many of today’s most pressing topics - thank you to the brilliant minds who joined us in driving these important conversations forward.
- [HydraScreen: A Generalizable Structure-Based Deep Learning Approach to Drug Discovery](https://juvlabs.com/news/publications/hydrascreen-a-generalizable-structure-based-deep-learning-approach-to-drug-discovery/) - We propose HydraScreen, a deep-learning framework for safe and robust accelerated drug discovery. HydraScreen utilizes a state-of-the-art 3D convolutional neural network designed for the effective representation of molecular structures and interactions in protein–ligand binding. We designed an end-to-end pipeline for high-throughput screening and lead optimization, targeting applications in structure-based drug design. We assessed our approach
- [Ro5 Bioactivity Lab: Identification of Drug Candidates for COVID-19](https://juvlabs.com/news/publications/ro5-bioactivity-lab-identification-of-drug-candidates-for-covid-19/) - The public health emergency known as the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a large number of deaths worldwide and major socioeconomic disruption. To date, no broadly effective antiviral treatment or vaccine has been developed for COVID-19. In response to this dire situation, Ro5
- [SE(3) Equivariant Topologies for Structure-based Drug Discovery](https://juvlabs.com/news/publications/se3-equivariant-topologies-for-structure-based-drug-discovery/) - Abstract Modeling protein-ligand interactions is a challenging task that has been approached through an array of perspectives. From physics-based computational approaches to vast deep learning pipelines, in silico methods hold promise in reducing experimental overhead in the otherwise tedious and costly drug discovery campaigns. We introduce Protein-Ligand Equivariant Transformer (ProLET), a generalizable model built upon
- [Benchmarking ML in ADMET predictions: the practical impact of feature representations in ligand-based models](https://juvlabs.com/news/publications/benchmarking-ml-in-admet-predictions-the-practical-impact-of-feature-representations-in-ligand-based-models/) - Abstract This study, focusing on predicting Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) properties, addresses the key challenges of ML models trained using ligand-based representations. We propose a structured approach to data feature selection, taking a step beyond the conventional practice of combining different representations without systematic reasoning. Additionally, we enhance model evaluation methods by
- [Accelerated hit identification with target evaluation, deep learning and automated labs: prospective validation in IRAK1](https://juvlabs.com/news/publications/accelerated-hit-identification-with-target-evaluation-deep-learning-and-automated-labs-prospective-validation-in-irak1/) - Abstract Background Target identification and hit identification can be transformed through the application of biomedical knowledge analysis, AI-driven virtual screening and robotic cloud lab systems. However there are few prospective studies that evaluate the efficacy of such integrated approaches. Results We synergistically integrate our in-house-developed target evaluation (SpectraView) and deep-learning-driven virtual screening (HydraScreen) tools with
- [The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’](https://juvlabs.com/news/in-the-news/the-simple-biotech-podcast-investing-in-the-longevity-industry-the-greatest-investment-opportunity-in-human-history/) - What makes longevity one of the greatest investment opportunities in human history?
- [Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan](https://juvlabs.com/news/press-releases/juvenescence-acquires-ai-drug-discovery-company-ro5-to-boost-rd-capabilities-and-drive-pipeline-of-medicines-to-extend-healthy-lifespan/) - Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to
- [Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership](https://juvlabs.com/news/press-releases/juvenescence-closes-76m-first-tranche-of-series-b-1-financing-led-by-abu-dhabis-m42-alongside-strategic-partnership/) - Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking strategic partnership with M42 to collaborate in drug discovery Juvenescence aims to complete the financing in Q3 2025 to advance clinical pipeline targeting age-related diseases Ramsey, Isle
- [Biomarkers of Aging Consortium](https://juvlabs.com/news/juv-on-the-road/biomarkers-of-aging-consortium/) - I had the best time attending the 2024 Biomarkers of Aging Consortium Conference at Harvard Medical School !
- [The Longevity Forum](https://juvlabs.com/news/juv-on-the-road/the-longevity-forum/) - Bridging science and society to help achieve longer, healthier and more fulfilled lives for as many people as possible.
- [Buck Institute for Research on Aging](https://juvlabs.com/news/juv-on-the-road/buck-institute-for-research-on-aging/) - This week, four members of the Juvenescence® team—Kersten Small, Jeff Madwed, Steve Felstead, and myself—had the privilege of visiting the Buck Institute for Research on Aging.
- [WHX Dubai](https://juvlabs.com/news/juv-on-the-road/whx-dubai/) - Reflecting on an inspiring & productive week at WHX Dubai - with the latest & best in healthcare innovation.
- [Hevolution Foundation](https://juvlabs.com/news/juv-on-the-road/hevolution-foundation/) - Our co-founder Dr. Greg Bailey took to the stage in Riyadh at Hevolution Foundation hashtag#GHS2025 with fellow investment leaders.
- [Incredible week at Abu Dhabi Global Health Week](https://juvlabs.com/news/juv-on-the-road/incredible-week-at-abu-dhabi-global-health-week/) - Packed with bold ideas, global collaboration, and a shared vision for a future built on preventative, personalised healthcare.
- [First day at the The Longevity Forum in London](https://juvlabs.com/news/juv-on-the-road/first-day-at-the-the-longevity-forum-in-london/) - A fantastic first day at the The Longevity Forum in London, filled with valuable insights.
- [Morphoceuticals](https://juvlabs.com/news/press-releases/morphoceuticals/) - Listen in to Prof Michael Levin & Prof David Kaplan discussing the Morphoceuticals vision and groundbreaking approach of mapping & manipulating the bioelectrome to induce regeneration.
- [Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration](https://juvlabs.com/news/press-releases/data-and-safety-monitoring-board-approves-lygenesiss-phase-2a-clinical-trial-to-continue-and-dose-escalate-in-novel-trial-of-organ-regeneration/) - The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease.
- [Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm](https://juvlabs.com/news/in-the-news/relation-therapeutics-secures-35-million-of-new-seed-financing-led-by-dcvc-and-co-lead-nventures-nvidias-venture-arm/) - Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
- [Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.](https://juvlabs.com/news/press-releases/chrysea-unveils-groundbreaking-findings-on-spermidine-dietary-intake-and-cardiovascular-health-at-american-physiological-society-aps-summit/) - Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.
- [Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m](https://juvlabs.com/news/in-the-news/relation-therapeutics-announces-two-strategic-collaborations-with-gsk-to-the-tune-of-300m/) - Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company. Onward!
- [M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence](https://juvlabs.com/news/press-releases/m42-announces-strategic-investment-and-partnership-with-leading-biotech-juvenescence/) - M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.
- [What Is Metabolic Age and Why It Should Matter to You](https://juvlabs.com/news/in-the-news/what-is-metabolic-age-and-why-it-should-matter-to-you/) - Everyone ages — it’s one of the indisputable facts of life. From the moment we are born, each one of us starts a linear process of growth and maturation
- [Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics](https://juvlabs.com/news/press-releases/juvenescence-the-buck-institute-and-insilico-medicine-establish-napa-therapeutics/) - The Buck Institute is one of the leading research centers in the world focused solely on research on aging and the elimination of age-related disease.
- [Juvenescence Capitalizes BYOMass](https://juvlabs.com/news/press-releases/juvenescence-capitalizes-byomass/) - Juvenescence is pleased to announce its latest equity investment in BYOMass Inc.
- [Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments](https://juvlabs.com/news/press-releases/juvenescence-confirms-close-of-souvien-therapeutics-and-announces-high-level-appointments/) - Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
- [Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’](https://juvlabs.com/news/in-the-news/longevity-technology-greg-bailey-on-democratizing-healthcare-paradigm-shifts-disruptive-technologies/) - Dr. Bailey discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an inflection point.
- [Forbes: AI And Optimism: Jim Mellon Wants Us All To Live Longer](https://juvlabs.com/news/in-the-news/forbes-ai-and-optimism-jim-mellon-wants-us-all-to-live-longer/) - Jim Mellon probably has a broader understanding of the progress being made confronting human aging than any other person alive.
- [BBC Science Focus Magazine: An End To Aging?](https://juvlabs.com/news/in-the-news/bbc-science-focus-magazine-an-end-to-aging/) - The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.
- [Juvenescence’s Latest Venture, MDI Therapeutics, Inc., Targeting Fibrotic Disease](https://juvlabs.com/news/press-releases/juvenescences-latest-venture-mdi-therapeutics-inc-targeting-fibrotic-disease/) - A biopharmaceutical company focused on treating aging and age-related disease
- [Longevity Secrets of the Experts](https://juvlabs.com/news/in-the-news/longevity-secrets-of-the-experts/) - Healthspan and longevity research has exploded in the past decade, and as scientists learn more about the biology of aging
- [Juvenescence Appoints Dr Richard Marshall CBE as CEO](https://juvlabs.com/news/press-releases/juvenescence-appoints-dr-richard-marshall-cbe-as-ceo/) - Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan.
- [M2Bio Sciences Interview: Dr. Greg Bailey Goes Deep on Juvenescence, Longevity Biotech, and His Personal Story](https://juvlabs.com/news/in-the-news/m2bio-sciences-interview-dr-greg-bailey-goes-deep-on-juvenescence-longevity-biotech-and-his-personal-story/) - Greg goes deep on Juvenescence, longevity biotech and his personal story.
- [Longevity Technology: Equity investment in MDI Therapeutics by Juvenescence will develop novel serpin-based therapies](https://juvlabs.com/news/in-the-news/longevity-technology-equity-investment-in-mdi-therapeutics-by-juvenescence-will-develop-novel-serpin-based-therapies/) - Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
- [THE BUCK INSTITUTE, WHERE THE PROMISE OF AGING RESEARCH ISN’T LONGEVITY](https://juvlabs.com/news/in-the-news/the-buck-institute-where-the-promise-of-aging-research-isnt-longevity/) - The leaders of the Buck Institute for Research on Aging want you to know that they’re not going to make you immortal.
- [Juvenescence Chairman explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.](https://juvlabs.com/news/in-the-news/juvenescence-chairman-explains-why-investing-in-longevity-has-the-potential-to-deliver-significant-financial-personal-and-humanitarian-returns/) - There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health
- [Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence](https://juvlabs.com/news/in-the-news/master-investor-2022-our-ceo-dr-greg-bailey-presents-juvenescence/) - The investment community is chasing a longer, healthier life like the rest of us.
- [Juvenescence: Think aging up, rather than disease down](https://juvlabs.com/news/in-the-news/juvenescence-think-aging-up-rather-than-disease-down/) - New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle.

## Pages

- [Biotech Company](https://juvlabs.com/) - We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- [Dr Rosalba](https://juvlabs.com/our-team/dr-rosalba/) - Dr. Rosalba PerronePrincipal Scientist Rosalba Perrone, PhD, is a Senior Research Scientist at Juvenescence with deep expertise in immune-metabolism and the biology of aging. With over six years of experience in biotech, Rosalba has played a key role in advancing early-stage therapeutics toward clinical development, with a focus on translational biology, preclinical study design, and anti-inflammatory assay development.
- [Our Team](https://juvlabs.com/our-team/) - Leaders in Biopharmaceutical Innovation Our leadership team is a coalition of disruptors with over 150 years of combined R&D experience and a history of delivering two of the 10 largest biopharma deals of the last century. They are committed to advancing the future of medicine, creating approved medicines, and consistently delivering value to our shareholders.
- [Dr. Carmel Nanthakumar](https://juvlabs.com/our-team/dr-carmel-nanthakumar/) - Dr. Carmel Nanthakumar, PhD, FRSBVP, Translational Biology Carmel Nanthakumar is a senior scientific leader in drug discovery, translational biology and clinical development with over 20 years’ experience gained at GSK, AstraZeneca and Merck. At GSK, she held several high-level leadership and scientific roles leading global teams across pre-clinical and clinical development programmes. Carmel is especially interested in
- [Catherine McClinton](https://juvlabs.com/our-team/catherine-mcclinton/) - Catherine McClintonHead of Clinical Operations Catherine McClinton is an accomplished Senior Operations leader bringing over 30 years of clinical expertise. Her career spans end-to-end operational delivery across complex global research — from Phase I to Phase II/III studies — consistently driving high-quality data and regulatory readiness whilst striving for on-target trial delivery. She regularly leads global training
- [Eileen Jennings-Brown](https://juvlabs.com/our-team/eileen-jennings-brown/) - Eileen Jennings-BrownChief Technology & Transformation Officer Eileen Jennings-Brown is Chief Technology & Transformation Officer at Juvenescence. She leads the company’s technology strategy and enterprise transformation, with responsibility for building Juvenescence’s AI-enabled drug discovery capability and the digital foundations required to scale globally.Her remit also includes supporting Juvenescence’s regional build-out, putting in place the core capabilities needed to
- [Mohamad Hamade](https://juvlabs.com/our-team/mohamad-hamade/) - Dr. Mohamad HamadeManaging Director, GCC Dr. Mohamad Hamade is Managing Director for the GCC region at Juvenescence, where he leads the company’s regional strategy and expansion efforts, spearheading strategic partnerships and collaborations as Juvenescence deepens its presence across the GCC. Dr. Hamade is the Founder of LUMIO Capital, an investment platform driving high-impact ventures in healthcare
- [Dr Kersten Small](https://juvlabs.com/our-team/dr-kersten-small/) - Dr. Kersten SmallProject Leader Kersten is drug hunter, pharmaceutical scientist, and translational research leader with experience in multiple therapeutic areas at Merck Research Labs, Mitsubishi-Tanabe, and Cohen Veterans Biosciences. Kersten has a proven track record for pipeline building and enabling decision-making across all discovery and early development stage gates. Kersten is experienced in the identification and
- [Paul Russell](https://juvlabs.com/our-team/paul-russell/) - Paul RussellChief Development Officer A biochemist by training, Paul brings over 27 years’ experience in pharma and biotech, having led global projects for pre-clinical and clinical assets.Paul was most recently Head of Development at Enterprise Therapeutics Ltd where he led the strategy for all development programme activities (CMC, DMPK, toxicology and clinical) from candidate selection
- [Our Approach](https://juvlabs.com/our-approach/) - Our Approach 01 Juvenescence is the only longevity biotech with fully integrated AI-enabled drug discovery combined with a strategic portfolio model, uniquely positioned to accelerate the development of both treatments and preventive medicines. Our Unique Value Proposition 02 Computational Drug Discovery Our computational drug discovery capabilities are enhanced by incorporating state-of-the-art machine learning models and
- [Fiona McCarrick](https://juvlabs.com/our-team/fiona-mccarrick/) - Fiona McCarrickGeneral Counsel Fiona McCarrick, General Counsel at Juvenescence, is a qualified solicitor responsible for overseeing the group’s legal functions. Fiona has extensive experience in advising international life sciences companies across multiple jurisdictions and has been with Juvenescence since 2020.Fiona works closely with the Board, Leadership Team and other key stakeholders to support the Juvenescence
- [Yehudah Nevies](https://juvlabs.com/our-team/yehudah-nevies/) - Yehudah NeviesDirector Investor Relations Yehudah Nevies has a decade of experience in life science venture. Yehudah has been with Juvenescence for seven years, where he is responsible for investor relations and leading fundraising efforts. Previously, Yehudah played a key role in sourcing and diligencing therapeutic opportunities across the pipeline.Prior to joining Juvenescence, Yehudah was part
- [Jeff M Bio](https://juvlabs.com/our-team/jeff-m-bio/) - Dr. Jeff MadwedSenior Project Lead Jeff Madwed, PhD is currently Senior Project Lead at Juvenescence focused on advancing core medicines through clinical development. Jeff is an experienced drug hunter, pharmacologist and translational researcher who has led discovery and early development project teams at Boehringer Ingelheim, Merck Research Labs and Mitsubishi-Tanabe across multiple therapeutic areas. Jeff
- [Privacy Notice](https://juvlabs.com/privacy-notice/) - Privacy Notice At Juvenescence we care about your privacy and the trust you place in us by providing Personal Information and we want to be transparent about how we use it and how we protect it.This Privacy Notice (together with our Terms, which can be accessed at Terms of Service- JuvLabs.com Website – Juvenescence, and our
- [Our Pipeline](https://juvlabs.com/our-pipeline/) - CORE MEDICINES PIPELINE Leading Healthspan Innovations Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team, targeting fundamental aging mechanisms with a near-term age-related first indication identified for clinical development. PAI-1 Inhibitor GDF-15 mAb CD38 Inhibitor Ketone Rx Plasmalogen PORTFOLIO COMPANIES Our portfolio companies represent strategic investments across a diverse array of
- [Gillian Bio](https://juvlabs.com/our-team/gillian-bio/) - Gillian DinesChief Science Officer Gillian (Gill) Dines is a highly accomplished pharmaceutical executive with 30+ years of experience in research, development, approval, and commercialization of new medicines in both “Big Pharma” and as an entrepreneur in the Biotech environment. She has led the successfuldevelopment and global approval of medicines and devices in a number of
- [Dr Steve Felstead Mbchb](https://juvlabs.com/our-team/dr-steve-felstead-mbchb/) - Dr. Steve Felstead, MBChBChief Medical Officer Dr. Steve Felstead, MB-ChB, is Chief Medical Officer at Juvenescence. He is also Managing Director of Deljay Consulting Limited, providing services to Pharma, Biotech, and Venture Capital industries.“The science of longevity is endlessly fascinating,” he says, “The possibilities to impact people’s lives with our research drives us all here.”Dr.
- [Alexander Pickett](https://juvlabs.com/our-team/alexander-pickett/) - Alexander PickettManaging Director Alexander Pickett is Managing Director at Juvenescence, where he oversees new opportunity onboarding. Since 2014, he has worked with Juvenescence founding partners Greg, Jim, and Declan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank where he supported existing investments at Portage Biotech Inc., including Portage Pharma Ltd. and Biohaven (NYSE:BHVN).Alexander
- [David Gill Bio](https://juvlabs.com/our-team/david-gill-bio/) - David GillChief Financial Officer David Gill, the Chief Financial Officer of Juvenescence, is a Chartered Accountant (FCA) with extensive experience in both the US and UK in private and listed biotech companies.Previously Group Controller of the company, David was attracted to Juvenescence because of its exciting programs. He says, “Targeting both prevention and treatment of
- [Dr Richard Marshall Cbe Md Phd](https://juvlabs.com/our-team/dr-richard-marshall-cbe-md-phd/) - Dr. Richard Marshall, CBE, MD, PhDChief Executive Officer Dr. Richard Marshall is a physician scientist and a highly experienced executive with a 20-year track record of outstanding leadership in Pharmaceutical R&D. He is driven by a passion for developing new medicines to treat diseases of high unmet need and is excited to lead Juvenescence on
- [Dr Declan Doogan Md](https://juvlabs.com/our-team/dr-declan-doogan-md/) - Dr. Declan Doogan, MDBoard Member / Co-Founder Dr. Declan Doogan, MD, a co-founder of Juvenescence, was driven to start the company because he believes we all can do better in managing health as we get older.Dr. Doogan has more 30 years’ experience in the global pharmaceutical industry. He was Head of Worldwide Drug Development at
- [Jim Mellon](https://juvlabs.com/our-team/jim-mellon/) - Jim MellonDeputy Chairman / Co-Founder Jim Mellon, a co-founder and Deputy Chairman of Juvenescence, was inspired by the possibilities and advances being made in the area of longevity. He travelled across the world, speaking to leading scientists and researchers, and from those conversations, he wrote the book, Juvenescence. That book and his partnership with Greg Bailey
- [Dr Gregory Bailey Md](https://juvlabs.com/our-team/dr-gregory-bailey-md/) - Dr. Greg Bailey, MDExecutive Chairman / Co-Founder Dr. Greg Bailey, MD, a co-founder and the Executive Chairman of Juvenescence, is a physician, financier, and biotech entrepreneur with extensive experience founding and financing healthcare companies.Dr. Bailey is driven by the important opportunity to truly modify aging based on rigorous science. The goal: to use his track
- [Contact Us - Thank You](https://juvlabs.com/contact-us-thank-you/) - Get in Touch Send us an inquiry if you’d like to connect with one of our team members. For any product inquiries, please email care@juvlabs.com. Thank you for your submission.
- [Contact Us](https://juvlabs.com/contact-us/) - Get in Touch Send us an inquiry if you’d like to connect with one of our team members. For any product inquiries, please email care@juvlabs.com. Send Message
- [News](https://juvlabs.com/news/) - In the News Juv on the Road Press Releases Publications Videos All Press Releases Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor February 26, 2026 Press Releases Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City’s Life Science Innovation Cluster February 16, 2026 Videos Listen in to the interview to hear
- [Science](https://juvlabs.com/science/) - SCIENTIFIC APPROACH What Causes Aging? We base our work on breakthrough scientific discoveries that target the underlying biological causes of aging. 85% of older adults have at least one chronic health condition, and 60% have at least two. We believe that when aging slows, the onset of chronic disease will slow with it. Aging Accelerates
- [Terms Of Service](https://juvlabs.com/terms-of-service/) - Terms of Service Juvenescence Therapeutics Limited, (“Juvenescence,”, “Juvenescence Therapeutics,” “we,” “us,” “our”) provides its services to you through its website located at www.JuvTherapeutics.com (the “Site”). By visiting our site and/ or purchasing something from us, you engage in our “Service” and agree to be bound by the following Terms of Service (as amended from time
- [Professor Lynne Cox](https://juvlabs.com/our-team/professor-lynne-cox-bio/) - Professor Lynne Cox Lynne Cox, PhD is an Associate Professor of Biochemistry at the University of Oxford, the George Moody Fellow at Oriel, and Principal Investigator of the lab of Ageing and Cell Senescence at the Department of Biochemistry. She has expertise in the biological underpinnings of ageing and age-related diseases, specifically cell senescence and
- [Professor Hugh Montgomery](https://juvlabs.com/our-team/professor-hugh-montgomery-bio/) - Professor Hugh Montgomery OBE FMedSci MBBS BSc FRCP(Lond) FRCP (Ed) MD FRSB FFICM FRI FRGS Professor of Intensive Care Medicine, University College London.Hugh was appointed Officer of the Order of British Empire (OBE) for services to intensive care medicine and climate change. He is Professor of Intensive Care Medicine and Director of the UCL Centre
- [Professor Eric Verdin](https://juvlabs.com/our-team/professor-eric-verdin/) - Professor Eric Verdin Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Aging. He is one of the Longevity Science Foundation’s Scientific Advisory Board members. Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was the first to clone a family of
- [Martin Bio](https://juvlabs.com/our-team/martin-bio/) - Martin DuckerChief Science Officer - JuvVentures Martin Ducker is the Chief Science Officer of JuvVentures where he oversees the ideation and development of novel nutritional interventions to slow or reverse ageing.Martin joined Juvenescence as a post-doc in 2018 and has held a number of roles spanning business development, operations, and R&D. Prior to Juvenescence he
- [Denham Bio](https://juvlabs.com/our-team/denham-bio/) - Denham EkeBoard Member Denham Eke sits on Juvenescence’s board, having 25+ years’ experience in directorship roles of large organizations where he has been tasked with rationalizing and restructuring operations to enhance profitability. BACK TO PEOPLE
- [Media Podcasts](https://juvlabs.com/media-podcasts/) - In the News Juvenescence The Buck Institute All In the News Relation Therapeutics announces $1.7B strategic collaboration with Novartis to advance therapeutics for Atopic Diseases December 9, 2025 In the News Richards interview to Jo Shorthouse July 31, 2025 In the News Chrysea presents additional study results at Gordon Research Conference (GRC) July 31, 2025
- [Unsolicited Idea Submission Policy](https://juvlabs.com/unsolicited-idea-submission-policy/) - Unsolicited Idea Submission Policy Juvenescence and its affiliates, employees, contractors do not accept, review or consider any unsolicited ideas, works, products, product improvements, product names, creative materials, proposals, content or the like (“Submissions”). The purpose of this policy is to avoid potential misunderstandings or disputes.Please do not send or provide any Submissions in any form
- [Refund Policy](https://juvlabs.com/refund-policy/) - Refund Policy Your satisfaction is our top priority! You may return your unopened purchase within 30 days and receive a refund in the original form of payment.To start a return, please contact Customer Care at care@juvlabs.com. Upon receipt of your return we will issue a refund to your original form of payment.
- [Cookie Notice](https://juvlabs.com/cookie-notice/) - Cookie Notice Introduction to CookiesWe use cookies, clear GIFs (also known as web beacons, web bugs or pixel tags), and other tracking technologies to collect information on our website to personalise content and digital advertising, provide social media features and analyse traffic. This notice refers to both cookies and similar technologies as cookies.You can accept
- [Solutions](https://juvlabs.com/solutions/) - Realize biotechnology with the solutions that we offer. Our relentless pursuit of scientific excellence propels us toward groundbreaking discoveries that transform lives and shape the future of medicine. Request a demo Functionalities Suitable solutions for your research needs The current age of scientific advancement has resulted in a proliferation of novel innovations in various domains

## My Templates

- [Elementor Single Post #5897](https://juvlabs.com/?elementor_library=elementor-single-post-5897) - Elementor Single Post #5897 February 4, 2026 Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following recent
- [System And Method For Automated Pharmaceutical Research Utilizing Context Workspaces](https://juvlabs.com/?elementor_library=system-and-method-for-automated-pharmaceutical-research-utilizing-context-workspaces) - Content area
- [System And Method For Automated Retrosynthesis](https://juvlabs.com/?elementor_library=system-and-method-for-automated-retrosynthesis) - Content area
- [Data Platform For Automated Pharmaceutical Research Using Knowledge Graph](https://juvlabs.com/?elementor_library=data-platform-for-automated-pharmaceutical-research-using-knowledge-graph) - Content area
- [System And Method For Prediction Of Protein-Ligand Interactions And Their Bioactivity](https://juvlabs.com/?elementor_library=system-and-method-for-prediction-of-protein-ligand-interactions-and-their-bioactivity) - Content area
- [System And Method For Biomarker-Outcome Prediction And Medical Literature Exploration](https://juvlabs.com/?elementor_library=system-and-method-for-biomarker-outcome-prediction-and-medical-literature-exploration) - Content area
- [System And Method For Prediction Of Protein-Ligand Bioactivity Using Point-Cloud Machine Learning](https://juvlabs.com/?elementor_library=system-and-method-for-prediction-of-protein-ligand-bioactivity-using-point-cloud-machine-learning) - Content area
- [System And Method For Molecular Reconstruction And Probability Distributions Using A 3d Variational - Conditioned Generative Adversarial Network](https://juvlabs.com/?elementor_library=system-and-method-for-molecular-reconstruction-and-probability-distributions-using-a-3d-variational-conditioned-generative-adversarial-network) - Content area
- [System And Method For Prediction Of Protein-Ligand Bioactivity And Pose Propriety](https://juvlabs.com/?elementor_library=system-and-method-for-prediction-of-protein-ligand-bioactivity-and-pose-propriety) - Content area
- [Toxic Substructure Extraction Using Clustering And Scaffold Extraction](https://juvlabs.com/?elementor_library=toxic-substructure-extraction-using-clustering-and-scaffold-extraction) - Content area
- [Posts Loop](https://juvlabs.com/?elementor_library=elementor-loop-item-2) - Posts Loop May 12, 2025
- [Single Post Template](https://juvlabs.com/?elementor_library=elementor-single-post-1485) - Single Post Template March 7, 2024 Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following recent appointments
- [News](https://juvlabs.com/?elementor_library=elementor-loop-item) - News March 5, 2024
- [Default Kit](https://juvlabs.com/?elementor_library=default-kit)
- [Coming Soon](https://juvlabs.com/?elementor_library=coming-soon)

## Theme Builder

- [Biotech Company - Footer](https://juvlabs.com/?uicore-tb=biotech-company-footer) - Join Our Mission to Extend healthspan Contact Us Science Our Approach Team Pipeline News Science Our Approach Team Pipeline News Subscribe now to stay up to date on news from our team. Subscribe © Juvenescence Privacy Policy Terms and Conditions

## Categories

- [Press Releases](https://juvlabs.com/news/category/press-releases/)
- [In the News](https://juvlabs.com/news/category/in-the-news/)
- [Juv on the Road](https://juvlabs.com/news/category/juv-on-the-road/)
- [Publications](https://juvlabs.com/news/category/publications/)
- [Videos](https://juvlabs.com/news/category/videos/)

## Tags

- [Juvenescence](https://juvlabs.com/news/tag/juvenescence/)
- [MDI Therapeutics](https://juvlabs.com/news/tag/mdi-therapeutics/)
- [Napa Therapeutics](https://juvlabs.com/news/tag/napa-therapeutics/)
- [Souvien Therapeutics](https://juvlabs.com/news/tag/souvien-therapeutics/)
- [The Buck Institute](https://juvlabs.com/news/tag/the-buck-institute/)